Vaginal progesterone for the prevention of recurrent spontaneous preterm birth.
Publication/Presentation Date
10-1-2023
Abstract
After the United States Food and Drug Administration pulled 17-alpha hydroxyprogesterone caproate from the market for its use in prevention of recurrent spontaneous preterm birth, national societies have had mixed recommendations regarding the management of patients with a singleton pregnancy and previous spontaneous preterm birth. Herein we highlight the randomized trial data and translational evidence supporting the use of vaginal progesterone for prevention of recurrent spontaneous preterm birth in singleton pregnancies. Prophylactic vaginal progesterone starting at 16 weeks and 0 days every night should be offered to patients with singletons and previous singleton spontaneous preterm birth regardless of cervical length, and continued along with placement of cerclage if a transvaginal ultrasound cervical length ≤25 mm is detected at < 24 weeks.
Volume
5
Issue
10
First Page
101116
Last Page
101116
ISSN
2589-9333
Published In/Presented At
Berghella, V., Gulersen, M., Roman, A., & Boelig, R. C. (2023). Vaginal progesterone for the prevention of recurrent spontaneous preterm birth. American journal of obstetrics & gynecology MFM, 5(10), 101116. https://doi.org/10.1016/j.ajogmf.2023.101116
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
37543143
Department(s)
Administration and Leadership
Document Type
Article